Navigation Links
Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
Date:2/14/2013

JERUSALEM, February 14, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has been in communication with the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application for oral insulin. The FDA has asked Oramed to perform a sub study in a controlled in-patient setting for up to a one-week period. In order to accommodate the FDA's request, Oramed will submit a new IND with a clinical protocol for the aforementioned sub study.

"We are very pleased to be in close and positive communications with the FDA, as well as having a clear path which meets the FDA's input. This positions us for imminent clearance from the FDA to proceed with our planned clinical studies," commented Nadav Kidron , CEO of Oramed.  

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under U.S. IND, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
2. Oramed Pharmaceuticals Announces Reverse Stock Split
3. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
4. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
5. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
6. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
7. DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
8. Todays Research on Mylan and Watson Pharmaceuticals: One Drug Makers Sorrow is Another Ones Joy
9. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
10. UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
11. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... university inventions licensed to biotechnology firms has revealed ... open these roadblocks, the researchers suggest that better ... stage could lead to faster commercialization down the ... discoveries made in university laboratories and licensed to ... trials, which have a high failure rate. But ...
(Date:8/20/2014)... Aug. 20, 2014 Neurotrope, Inc. (OTCQB: ... conference call to provide an update on Company ... daylight timeDial-in numbers:(888) 505-4369 (U.S. and Canada) or ... cast: www.neurotropebioscience.com , under "Investor Relations"The teleconference replay ... through September 2, 2014 at (888) 203-1112 (U.S. ...
(Date:8/20/2014)... Aug. 20, 2014  PAREXEL International Corporation (NASDAQ: ... presenting at the Baird Healthcare Conference in New York.  ... Financial Officer, will be making a presentation on PAREXEL ... Wednesday, Sept. 3, 2014. A live webcast ... section of PAREXEL,s website at www.PAREXEL.com in ...
(Date:8/20/2014)... , Aug. 20, 2014 /PRNewswire-iReach/ -- A ... transformative collaboration between the school,s bioengineering department and ... of the Intel® Software Academic Program, UCSD,s research ... and the human body.  Photo ... study exhibits the work of Dr. Todd ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Neurotrope To Host Conference Call 2PAREXEL International To Present At Baird Healthcare Conference 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2
... (Nasdaq:,VICL) today announced that the company will report financial ... opening of trading on,Thursday, May 8, and conduct a ... provide a company update at noon Eastern Time on,Thursday, ... basis to any interested,parties. The company will provide details ...
... PRINCETON, N.J., May 1 Orchid Cellmark Inc.,(Nasdaq: ... testing,services, will release its first quarter 2008 financial results ... and is hosting a,conference call and webcast to discuss ... Management will discuss financial results for the first quarter,2008 ...
... Oncothyreon Inc. (Nasdaq:,ONTY) (TSX:ONY) today announced that ... application with the U.S. Food and Drug ... for the treatment of advanced cancers. Following ... 1 clinical trial of PX-866., "PX-866 ...
Cached Biology Technology:Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results 2Orchid Cellmark to Announce First Quarter 2008 Financial Results on May 8, 2008 2Oncothyreon files investigational new drug application for PX-866 oncology compound 2Oncothyreon files investigational new drug application for PX-866 oncology compound 3
(Date:8/19/2014)... Efforts must be made to decrease China,s increasing caesarean ... August) in BJOG: An International Journal of Obstetrics ... the highest caesarean delivery rates in the world. Of ... by caesarean. Although the exact rate is not known, ... China reports total caesarean rates ranging from 36% to ...
(Date:8/19/2014)... used in supermarkets to encourage healthier spending habits? A ... that very question by tracking the purchasing records in ... to rate the nutritional value of foods for sale. ... David Just, PhD, and Brian Wansink PhD, author of ... over 150 Hannaford Supermarkets in the Northeastern United States ...
(Date:8/19/2014)... and Network-Level Science, , Imagine if we had the ... was responding to global changes in real time. Such ... multiple decades of information about ecological responses to environmental ... of different ecosystem types. , In fact, this ... Network, which will soon celebrate its 35th anniversary. , ...
Breaking Biology News(10 mins):Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3This week from AGU: Long-term ecological research, predicting cholera outbreaks 2
... 29, 2010) -- Wind turbines may be one of ... larger they also get noisier, become more of an ... solution: ocean-based wind turbines. While offshore turbines already have ... where the tower extends directly into the seabed. That ...
... -- The U.S. Supreme Court ruled 5-4 Monday that a ... the ability to patent software should not be limited. ... the "machine or transformation" test is not the sole test ... however, cannot be patented. IEEE-USA was party to an ...
... the Arctic climate system may be more sensitive to greenhouse ... atmospheric carbon dioxide may be high enough to bring about ... University of Colorado at Boulder, the international study indicated that ... High Arctic during the Pliocene Epoch 2.6 to 5.3 million ...
Cached Biology News:Arctic climate may be more sensitive to warming than thought, says new study 2Arctic climate may be more sensitive to warming than thought, says new study 3Arctic climate may be more sensitive to warming than thought, says new study 4
... isolated fromStreptomyces griseolusthat inhibits protein synthesis. ... in eukaryote ribosomes. Reported to induce ... including promyelocytic leukemia cells, Jurkat cells, ... Initiates intracellular signals and immediate early ...
... RC DC protein assay kit I provides reagents ... in the presence of reducing agents and detergents. ... assay. The kit includes reagents and standards sufficient ... I, 250 ml RC reagent II, 250 ml ...
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
... state-of-the-art separation system using the asymmetric flow ... integrates easily with Wyatts multi-angle light scattering ... as the Optilab DSP. The combined system ... of the particles/molecules separated by the AFFF ...
Biology Products: